UA74968C2 - Amlodipine bezylate tablets with improved stability and process for their preparation - Google Patents
Amlodipine bezylate tablets with improved stability and process for their preparation Download PDFInfo
- Publication number
- UA74968C2 UA74968C2 UA20040705877A UA20040705877A UA74968C2 UA 74968 C2 UA74968 C2 UA 74968C2 UA 20040705877 A UA20040705877 A UA 20040705877A UA 20040705877 A UA20040705877 A UA 20040705877A UA 74968 C2 UA74968 C2 UA 74968C2
- Authority
- UA
- Ukraine
- Prior art keywords
- tablets
- amlodipine
- active ingredient
- tablet
- mass
- Prior art date
Links
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 title claims abstract description 14
- 229960000528 amlodipine Drugs 0.000 title abstract description 20
- 239000004480 active ingredient Substances 0.000 claims abstract description 33
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 19
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 19
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 19
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 19
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 13
- 239000000314 lubricant Substances 0.000 claims abstract description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims abstract description 6
- 229960004005 amlodipine besylate Drugs 0.000 claims description 31
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 20
- 238000003825 pressing Methods 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 4
- 239000012535 impurity Substances 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000007907 direct compression Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 230000032798 delamination Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical group [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0105345A HU226642B1 (en) | 2001-12-17 | 2001-12-17 | Amlodipine bezylate tablets having extended stability and process for producing the same |
| PCT/HU2002/000145 WO2003051364A1 (en) | 2001-12-17 | 2002-12-17 | Amlopidine bezylate tablets with improved stability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA74968C2 true UA74968C2 (en) | 2006-02-15 |
Family
ID=90000366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20040705877A UA74968C2 (en) | 2001-12-17 | 2002-12-17 | Amlodipine bezylate tablets with improved stability and process for their preparation |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1458384B1 (es) |
| AT (1) | ATE333877T1 (es) |
| AU (1) | AU2002353242A1 (es) |
| BG (1) | BG108807A (es) |
| CZ (1) | CZ2004791A3 (es) |
| DE (1) | DE60213464T2 (es) |
| EA (1) | EA006826B1 (es) |
| ES (1) | ES2269787T3 (es) |
| HR (1) | HRP20040582B1 (es) |
| HU (1) | HU226642B1 (es) |
| LT (1) | LT5241B (es) |
| LV (1) | LV13243B (es) |
| PL (1) | PL370420A1 (es) |
| RS (1) | RS54304A (es) |
| SK (1) | SK2862004A3 (es) |
| UA (1) | UA74968C2 (es) |
| WO (1) | WO2003051364A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006059217A1 (en) * | 2004-12-01 | 2006-06-08 | Ranbaxy Laboratories Limited | Stable solid dosage forms of amlodipine besylate and processes for their preparation |
| JO3239B1 (ar) | 2008-09-22 | 2018-03-08 | Novartis Ag | تركيبات جالينية من مركبات عضوية |
| JP4954961B2 (ja) * | 2008-10-06 | 2012-06-20 | 大日本住友製薬株式会社 | 光安定性の向上した組成物 |
| JP5689052B2 (ja) * | 2011-12-26 | 2015-03-25 | 大日本住友製薬株式会社 | 光安定性の向上した組成物 |
| EA030466B1 (ru) | 2012-02-17 | 2018-08-31 | Эгиш Дьёдьсердьяр Зрт. | Фармацевтическая композиция, обладающая улучшенной стабильностью |
| PL236001B1 (pl) | 2012-12-21 | 2020-11-30 | Adamed Spolka Z Ograniczona Odpowiedzialnoscia | Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję |
| US10350171B2 (en) | 2017-07-06 | 2019-07-16 | Dexcel Ltd. | Celecoxib and amlodipine formulation and method of making the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8608335D0 (en) * | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
| DE19857716A1 (de) * | 1998-12-15 | 2000-06-21 | Bayer Ag | Neue feste Formulierung von Metrifonat |
| WO2003032954A1 (en) * | 2001-10-17 | 2003-04-24 | Dr. Reddy's Laboratories Ltd. | Stabilized pharmaceutical formulations containing amlodipine maleate |
-
2001
- 2001-12-17 HU HU0105345A patent/HU226642B1/hu unknown
-
2002
- 2002-12-17 ES ES02788262T patent/ES2269787T3/es not_active Expired - Lifetime
- 2002-12-17 EP EP02788262A patent/EP1458384B1/en not_active Expired - Lifetime
- 2002-12-17 SK SK286-2004A patent/SK2862004A3/sk unknown
- 2002-12-17 DE DE60213464T patent/DE60213464T2/de not_active Expired - Fee Related
- 2002-12-17 PL PL02370420A patent/PL370420A1/xx not_active IP Right Cessation
- 2002-12-17 EA EA200400801A patent/EA006826B1/ru not_active IP Right Cessation
- 2002-12-17 AU AU2002353242A patent/AU2002353242A1/en not_active Abandoned
- 2002-12-17 CZ CZ2004791A patent/CZ2004791A3/cs unknown
- 2002-12-17 UA UA20040705877A patent/UA74968C2/uk unknown
- 2002-12-17 WO PCT/HU2002/000145 patent/WO2003051364A1/en active IP Right Grant
- 2002-12-17 RS YU54304A patent/RS54304A/sr unknown
- 2002-12-17 AT AT02788262T patent/ATE333877T1/de not_active IP Right Cessation
-
2004
- 2004-06-23 HR HR20040582A patent/HRP20040582B1/xx not_active IP Right Cessation
- 2004-07-07 LT LT2004062A patent/LT5241B/lt not_active IP Right Cessation
- 2004-07-16 LV LVP-04-82A patent/LV13243B/en unknown
- 2004-07-16 BG BG108807A patent/BG108807A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LT2004062A (en) | 2005-02-25 |
| HU226642B1 (en) | 2009-05-28 |
| SK2862004A3 (en) | 2004-11-03 |
| RS54304A (en) | 2006-12-15 |
| HRP20040582B1 (en) | 2007-08-31 |
| DE60213464T2 (de) | 2007-03-01 |
| DE60213464D1 (de) | 2006-09-07 |
| ATE333877T1 (de) | 2006-08-15 |
| CZ2004791A3 (cs) | 2004-10-13 |
| BG108807A (en) | 2005-03-31 |
| WO2003051364A1 (en) | 2003-06-26 |
| HRP20040582A2 (en) | 2005-02-28 |
| HUP0105345A2 (hu) | 2003-12-29 |
| EP1458384A1 (en) | 2004-09-22 |
| LT5241B (lt) | 2005-07-25 |
| PL370420A1 (en) | 2005-05-30 |
| ES2269787T3 (es) | 2007-04-01 |
| AU2002353242A1 (en) | 2003-06-30 |
| HUP0105345A3 (en) | 2007-08-28 |
| EP1458384B1 (en) | 2006-07-26 |
| LV13243B (en) | 2005-05-20 |
| EA006826B1 (ru) | 2006-04-28 |
| EA200400801A1 (ru) | 2004-12-30 |
| HUP0105345D0 (en) | 2002-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gohel et al. | Preparation and assessment of novel coprocessed superdisintegrant consisting of crospovidone and sodium starch glycolate: a technical note | |
| KR20120078751A (ko) | 발사르탄 및 암로디핀의 고체 투여 형태 및 이의 제조 방법 | |
| MX2012000892A (es) | Formas de dosificacion de citrato ferrico. | |
| JP7116277B2 (ja) | 顆粒剤、並びに錠剤及びその製造方法 | |
| EP3749286A1 (en) | A pharmaceutical composition comprising metamizole, drotaverine, and caffeine | |
| UA74968C2 (en) | Amlodipine bezylate tablets with improved stability and process for their preparation | |
| JP2009513530A5 (es) | ||
| WO2008020990A1 (en) | New direct compressible excipient blend | |
| Aljaberi et al. | Tableting functionality evaluation of Prosolv Easytab in comparison to physical mixtures of its individual components | |
| JP2004521890A (ja) | 非吸湿性バルプロ酸ナトリウム組成物の製造方法 | |
| JP5644167B2 (ja) | 溶出改善されたケトチフェン又はその塩を含有する固形製剤 | |
| IES20070122A2 (en) | A process for the preparation of an orally administered unit dose tablet | |
| CZ290911B6 (cs) | Stabilní prostředky obsahující levosimendan a kyselinu alginovou | |
| Vinoth Kumar et al. | Formulation and evaluation of orodispersible liquisolid compacts of nifedipine using co-processed superdisintegrants | |
| JP2006257049A (ja) | 生菌剤や消化酵素剤およびその両方を含有する錠剤の製造方法およびそれによる錠剤 | |
| JP6037687B2 (ja) | グリメピリドを含有する口腔内崩壊錠 | |
| SINGH et al. | Effect of ZEIN on ciprofloxacin floating tablets | |
| AU632376B2 (en) | Pressing not delayed release of active compound, process for its production and use of polyhydroxybutyric acid for the production of such a pressing | |
| Kushare et al. | Design and Development of a Microwave Generated Lactose Monohydrate-Microcrystalline Cellulose Based Multifunctional Excipient Composites for Tablet Formulation using Box–Behnken Design | |
| Mohammed et al. | Effects of a co-processed novel multifunctional excipient on the tablet properties of metronidazole | |
| Kumar et al. | Formulation and evaluation of hydralazine hydrochloride mouth dissolving tablet for the management of eclampsia and pre-eclampsia | |
| EP2692342A1 (en) | Process for the preparation of pharmaceutical compositions comprising febuxostat in the form of tablets | |
| Patnala et al. | Improvement of Solubility and Dissolution Rate of Poorly Water-Soluble Anti-Cholestermic Drug Atorvastatin by Solid Dispersion Technique | |
| Asker et al. | Effect of scaling-up and formulation factors on the qualities of prednisone tablets | |
| Karthikeyan et al. | Formulation And Evaluation Of Zolpidem Tartrate Extended Release Matrix Tablets |